| 摘要 |
The invention concerns a cytotoxic, MDR-associated substance for producing a therapeutic agent for tumor therapy, which is characterized by a) the tumor cells of a tumor patient are chemosensitized with a cytokine, b) the scope of expression of one or more MDR-associate genes (e.g. mdrl, Mrp, Lrp) in the tumor tissues of the patient is determined according to the beginning of the cytokine treatment, c) the time domain is determined, in which the expression of one or more MDR-associate genes is substantially reduced by the cytokine treatment, d) the patient is treated in the determined time domain ("therapeutic window") with a therapeutically effective amount of a cytotoxic, MDR-associated substance, the effectiveness of which is influenced (enhanced) by the expression of one or more MDR-associate genes. The use of said substance leads to an improved tumor therapy.
|
